Roche reports 6% H1 sales growth to $37.28 billion, maintains full-year guidance

Roche Holding achieved a 6% increase in first-half sales, driven primarily by its pharmaceutical division. The company reaffirmed its full-year financial outlook, signaling stability in its core business performance.